Trial · NCT01369498
Results by group114
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 114
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score | Stage 1: SIM 200 mg | 0 | 90% Confidence Interval 0.0 to 23.8 | percentage of participants | |
| Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score | Stage 1: SIM 700 mg | 16.7 | 90% Confidence Interval 3.0 to 43.8 | percentage of participants | |
| Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score | Stage 2: SIM 200 mg+Ruxolitinib | 6.7 | 90% Confidence Interval 0.3 to 27.9 | percentage of participants | |
| Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score | Stage 2: SIM 700 mg+Ruxolitinib | 13.3 | 90% Confidence Interval 2.4 to 36.3 | percentage of participants | |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 1: SIM 200 mg | Week 12 | 0 | 90% Confidence Interval 0.0 to 25.9 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 1: SIM 700 mg | Week 12 | 0 | 90% Confidence Interval 0.0 to 25.9 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 2: SIM 200 mg+Ruxolitinib | Week 12 | 0 | 90% Confidence Interval 0.0 to 28.3 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 2: SIM 700 mg+Ruxolitinib | Week 12 | 0 | 90% Confidence Interval 0.0 to 25.9 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 1: SIM 200 mg | Week 24 | 0 | 90% Confidence Interval 0.0 to 25.9 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 1: SIM 700 mg | Week 24 | 0 | 90% Confidence Interval 0.0 to 25.9 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 2: SIM 200 mg+Ruxolitinib | Week 24 | 0 | 90% Confidence Interval 0.0 to 28.3 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 2: SIM 700 mg+Ruxolitinib | Week 24 | 0 | 90% Confidence Interval 0.0 to 25.9 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 1: SIM 200 mg | Any Time Post-Baseline | 0 | 90% Confidence Interval 0.0 to 25.9 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 1: SIM 700 mg | Any Time Post-Baseline | 0 | 90% Confidence Interval 0.0 to 25.9 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 2: SIM 200 mg+Ruxolitinib | Any Time Post-Baseline | 11.1 | 90% Confidence Interval 0.6 to 42.9 | percentage of participants |
| Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC) | Stage 2: SIM 700 mg+Ruxolitinib | Any Time Post-Baseline | 0 | 90% Confidence Interval 0.0 to 25.9 | percentage of participants |
| Percentage of Participants With Adverse Events (AEs) | Stage 1: SIM 200 mg | 100 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Stage 1: SIM 700 mg | 100 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Stage 2: SIM 200 mg+Ruxolitinib | 100 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Stage 2: SIM 700 mg+Ruxolitinib | 100 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01369498/results